Abbott opens new R&D facility in Illinois

The new facility provides leading capabilities for the formulation of new investigational medicines that have the potential to treat cancer and other deadly diseases. The center’s technology and equipment will help enable Abbott to expedite its development programs, potentially bringing innovative new pharmaceuticals to patients faster.

The formulation development center supports programs for both potent and non-potent oral compounds. This includes state-of-the-art capabilities for the safe formulation of potent compounds, such as cancer therapies, that are increasingly becoming more effective at low-dose levels.

The center was specifically designed with cutting-edge equipment and improvements to advance the R&D process, including automated technologies that reduce the time for preparing, producing and refining pilot drug formulations.

John Leonard, senior vice president of pharmaceuticals, R&D at Abbott, said: “The new formulation center is a clear example of Abbott’s commitment to advancing scientific innovation. With the growing number of compounds in Abbott’s pipeline, the new center utilizes the latest technology to accelerate the development of future medicines.”